XERS News and Press, Xeris Pharmaceuticals Inc. From 05/12/22

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced it is presenting new data on the burden of illness in Cushing’s sy...

Xeris Biopharma Holdings, Inc. (XERS) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Allison Wey - SVP, IR & Corporate Communications Paul Edick - Chairman & CEO Steve Pieper - CFO Conference Call Participants David Amsellem - Piper Sandler Roanna Ruiz -...

Xeris Pharma (NASDAQ:XERS -8.1%) stock fell after the company posted lower-than-expected Q1 net product revenue. Net Product Revenue rose 172% Y/Y to $21.91M, but missed analysts estimates by $1.48M. Net Loss for the first quarter was $33.7 million, or $0.25 per share (in-line with estim...

Xeris Pharmaceuticals press release (NASDAQ:XERS): Q1 GAAP EPS of -$0.25 in-line. Net Product Revenue of $21.91M (+172.2% Y/Y) misses by $1.48M. Cash, cash equivalents, and short-term investments at March 31, 2022 was $132.1 million compared to $102.4 million at December 31, 2021. Affirming 2...

Launched Recorlev® and Gvoke® Kit Achieved Q1 net product revenue of $21.9M – a 33% increase from same period prior year on a pro forma basis Ended Q1 with $132.1M in cash, cash equivalents and short-term investments Affirming 2022 guidance for...

Xeris Pharmaceuticals (NASDAQ:XERS) is scheduled to announce Q1 earnings results on Wednesday, May 11th, before market open. The consensus EPS Estimate is -$0.24 (+20.0% Y/Y) and the consensus Revenue Estimate is $23.39M (+190.6% Y/Y). Over the last 2 years, XERS has beaten EPS estimates 88% ...

Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that the Company wil...

First ready-to-use liquid glucagon available in a single-dose vial and syringe kit for rescue Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and g...

Xeris Biopharma Holdings, Inc. (XERS) Q4 2021 Earnings Conference Call March 10, 2022, 08:30 AM ET Company Participants Allison Wey - SVP, IR and Corporate Communications Paul Edick - Chairman and CEO Steve Pieper - CFO Conference Call Participants Roanna Ruiz - SVB Leerink Vamil Divan - Mizu...

Xeris Biopharma (NASDAQ:XERS) entered into a senior secured term loan agreement with funds managed by Hayfin Capital Management for providing the company with up to a total of $150M of capital. "Together with the recent equity financing, which closed in January, Xeris has now added ~$80M...